This study investigated the relative contribution of ion-trapping, microsomal binding, and distribution of unbound drug as determinants in the hepatic retention of basic drugs in the isolated perfused rat liver. The ionophore monensin was used to abolish the vesicular proton gradient and thus allow an estimation of ion-trapping by acidic hepatic vesicles of cationic drugs. In vitro microsomal studies were used to independently estimate microsomal binding and metabolism. Hepatic vesicular ion-trapping, intrinsic elimination clearance, permeability-surface area product, and intracellular binding were derived using a physiologically based pharmacokinetic model. Modeling showed that the ion-trapping was significantly lower after monensin treatment for atenolol and propranolol, but not for antipyrine. However, no changes induced by monensin treatment were observed in intrinsic clearance, permeability, or binding for the three model drugs. Monensin did not affect binding or metabolic activity in vitro for the drugs. The observed ion-trapping was similar to theoretical values estimated using the pHs and fractional volumes of the acidic vesicles and the pK a values of drugs. Lipophilicity and pK a determined hepatic drug retention: a drug with low pK a and low lipophilicity (e.g., antipyrine) distributes as unbound drug, a drug with high pK a and low lipophilicity (e.g., atenolol) by ion-trapping, and a drug with a high pK a and high lipophilicity (e.g., propranolol) is retained by ion-trapping and intracellular binding. In conclusion, monensin inhibits the ion-trapping of high pK a basic drugs, leading to a reduction in hepatic retention but with no effect on hepatic drug extraction.
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Basic lipophilic compounds are characterized by a high volume of distribution as a result of extensive tissue uptake. The main mechanisms of such a distribution pattern are nonspecific binding to membrane phospholipids (Bickel and Steele, 1974; Francesco and Bickel, 1977; Romer and Bickel, 1979) , binding to microsomal protein (Hung et al., 2002) , and the sequestration of the compounds into acidic vesicular compartments such as lysosomes or mitochondria (Daniel et al., 1995) . A potential consequence of an apparent irreversible sequestration of basic drugs into acidic vesicles is a potentially reduced drug bioavailability (de Duve et al., 1974; Ohkuma and Poole, 1978) or drug interactions (Daniel and Wojcikowski, 1999b; Nebbia et al., 1999) . Lysosomal trapping of basic lipophilic drugs has also been demonstrated to be an important determinant of disposition for desipramine and chloroquine and psychotropic compounds such as the piperidine and piperazine-type neuroleptics (Daniel et al., 2001) . The lysosomotropic properties of basic drugs are particularly important determining drug disposition and pharmacokinetics in lysosome-rich organs such as lungs, kidneys, or the liver.
Specific studies determining the relative contribution of ion-trapping and microsomal binding to the hepatic retention of drugs or relating the relative uptake to the physicochemical properties of drugs do not seem to have been undertaken so far and are the focus of the present study. Fluorescence microscopy, acridine orange staining, and other studies using primary hepatocyte cultures have shown that H ϩ ionophores, such as the carboxylic antibiotic monensin, abolish the pH gradient in the approximately 170 acidic vesicles in hepatocytes (Lake et al., 1987) . Such studies have not been carried out in the isolated perfused rat liver, which not only retains intact cellular integrity and fully functional lysosomes but allows the effects of drug structure on hepatocyte wall per-meability, hepatic binding, sequestration, and metabolism to be described (Hung et al., 2001 (Hung et al., , 2002 . Monensin infusions should allow the acidic vesicle pH gradient (and thus the ability for ion-trapping of basic drugs) to be experimentally abolished without affecting other permeation, binding, and clearance processes.
To evaluate the importance of physicochemical drug characteristics such as lipophilicity and pK a on ion-trapping and microsomal binding and thus drug retention, we compared two drugs with similar pK a values but different lipophilicity (apparent log octanol-water partition coefficient, log P app, atenolol and propranolol) and two drugs with a similar lipophilicity but different pK a (atenolol and antipyrine). The study follows up on the recently reported structure-hepatic disposition relationships of cationic drugs in normal and diseased rat liver (Hung et al., 2001 (Hung et al., , 2002 . Pharmacokinetic parameters such as hepatocellular influx, efflux, binding and elimination for the three drugs were determined and kinetic parameters were derived from an improved two-phase physiologically based organ pharmacokinetic model (Weiss and Roberts, 1996; Hung et al., 2001) , and the relative contribution of ion-trapping, intracellular binding, and unbound drug to hepatic drug retention was calculated. 
Materials and Methods Chemicals
Atenolol (4-[2-hydroxy-3-[(1-methylethyl)amino[propoxy]benze- neacetamide), antipyrine (1,2-dihydro-1,5-dimethyl-2-phenyl-3H- pyraol-3-one), monensin sodium (2-[5-ethyltetrahydro-5-[tetrahy- dro-3-methyl-5-[tetrahydro-6-hydroxy-6-(hydroxymethyl)-3,5- dimethyl-2H-pyran-2-yl]-2-furyl]-2-furyl]-9-hydroxy-␤-methoxy- ␣,␥,2,8-tetramethyl-1,6-dioxaspiro[4,5]decane-7-butyric sodium salt), propranolol (1-[(1-methylethyl)amino]-3-(1-naphtaleny- loxy)-2-propanol) all
In Situ Perfusion of the Isolated Rat Liver
The experimental protocol was approved by the University of Queensland Animal Ethics Committee. Perfusion of the isolated rat liver used in this study was performed as described previously (Cheung et al., 1996) . Briefly, male Wistar rats, weighing 200 to 250 g, were anesthetized using an intraperitoneal injection of xylazine/ketamine (10/80 mg kg Ϫ1 ). The laparotomized rats were heparinized with 200 units of heparin injected into the inferior vena cava. The bile duct and the portal vein were cannulated using polyethylene-10 (Clay Adams, Franklin Lakes, NJ) and an intravenous 16-gauge catheter, respectively. The liver was then perfused with 3-(Nmorpholino-)propanesulfonic acid (MOPS) buffer containing 2% bovine serum albumin and 15% washed canine red blood cells, adjusted to pH 7.4, and oxygenated via a silastic tubing lung with 100% pure oxygen. A noncirculating peristaltic pump was used as perfusion system. Once perfusion was established the animals were sacrificed by thoracotomy and the inferior vena cava was cannulated for sample collection. The animals were placed in a temperature-controlled environment at 37°C. Assessment of liver viability was by macroscopic appearance, measurement of bile flow, oxygen consumption, and portal resistance pressure (Cheung et al., 1996) .
Perfusions were adjusted to a flow rate of 15 ml/min and given a 10-min stabilizing period before the injection of the first bolus. Each bolus consisted of 50 l of buffer containing a given concentration of radiolabeled compound ([ 14 (Hung et al., 2001 ).
In Vitro Binding of Cationic Drugs to a Microsomal Protein Preparation
To assess the effect of monensin on hepatic drug binding and metabolism, an in vitro study with a microsomal protein preparation in the presence and absence of monensin was carried out, using buffer containing 0.35 mg/ml microsomal protein from normal livers. The unbound fraction of cationic drug in each buffer solution was estimated using an ultrafiltration method. A known concentration of the cationic drug stock solution was added to 500 l of each buffer solution to make final concentration of 0.05 M and placed in a centrifugal filter device (Microcon YM-30, 30,000 molecular weight cut-off; Millipore Corporation, Bedford, MA) and then centrifuged at 3000g for 10 min. The ultrafiltrate (in triplicate) was assayed by high-performance liquid chromatography. The fraction of drug unbound in the microsomal protein preparation (f uMP ) was determined as the ratio of the free concentration to total concentration of solute.
The impact of monensin on hepatic drug metabolism was assessed in these studies using intrinsic elimination clearance CL int in the presence and absence of monensin estimated by the formula CL int ϭ V max /(K m ϩ C), where V max is the maximum velocity, K m is the Michaelis-Menten constant, and C the concentration of the drug. The respective K m values were taken from the literature: antipyrine (Roberts and Rowland, 1986) , atenolol (Bagwell et al., 1989) , and propranolol (Ishida et al., 1992) . V max was determined by drug incubation with the microsomal protein preparation at 37°C and sampling at time points 0, 5, 10, and 20 min. The concentrations of drugs were analyzed by high-performance liquid chromatography (Hung et al., 2002) . Data were fitted to the formula and CL int estimated using Scientist (Micromath Scientist, Salt Lake City, UT) (Hung et al., 2001 (Hung et al., , 2002 . The perfused liver intrinsic clearance was based on the assumption that 70% of the harvested microsomal protein was metabolically active and an average amount of 50 mg of microsomal protein was obtained per gram of liver (Roberts and Rowland, 1986) .
Analytical Procedure
The high-performance liquid chromatography method used in this study has been described and validated previously (Hung et al., 2001 ).
Modeling and Data Fitting of the Outflow ConcentrationTime Profiles of Extracellular and Cellular References
Calculation of Intracellular pH (pH i ). Changes in intracellular pH were calculated according to the method of Le Couteur et al. (1993) .
Data Analysis
The two-phase physiologically based organ pharmacokinetic model describing intersinusoidal mixing (Roberts et al., 1988) , transfer across the hepatocyte membrane, and the intracellular distribution and elimination kinetics (Weiss and Roberts, 1996; Weiss et al., 1997) has been further developed to account for both the ion-trapping effect (K v , characterizing the acidic vesicular ion-trapping sites) and intracellular binding (K b , characterizing the total of intracellular binding) for the three model cationic. Briefly, as shown in Fig. 1 the model assumes drug transfer across the cytoplasmic membrane with influx and efflux rate constants k in and k out , respectively, recognizing
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The retention time distribution f y (t) of a drug after a single excursion in the cellular space for the resulting two-compartment cell model was obtained by standard methods in the Laplace domain,
[f y (t)], as described previously (Weiss, 1999; Weiss et al., 2000) .
where the influx rate constant k in ϭ f uB PS/V B , is the permeation clearance per extracellular volume V B , PS is the permeability-surface product, f uB is the unbound fraction of solute in the perfusate, and k cv and k vc represent the rate constant for transport from cytosol into the acidic compartment (lysosomes and mitochondria) or from acidic vesicles into cytosol, respectively, determining the equilibrium amount ratio K v ϭ k cv /k vc characterizing ion-trapping. K b is the equilibrium amount ratio characterizing the intracellular binding sites (microsomal and nonspecific binding) and the elimination rate constant defined as k e ϭ CL int /V C is the intrinsic elimination clearance normalized per cellular volume V C (Pang et al., 1995) . On comparison of the CL int obtained in microsomal metabolism studies with the one determined when K b was assigned as a slow distribution process, it was found that this resulted in an unrealistically high clearance rate. Therefore it was assumed that K b is characterized by an instantaneous distribution process (eliminating one fitting parameter at the same time). The hepatic transit time density function f(s) of solutes can be derived in terms of the extracellular transit time density of a nonpermeating reference molecule (sucrose) f B (s) (see eq. 2, and the density function of successive sojourn times f y (s) of the drug molecules into the cellular space
The fractional outflow versus time data were fitted in the time domain using a numerical inverse Laplace transformation of the appropriate transit time density function using the nonlinear regression program SCIENTIST (MicroMath Scientific Software). Data were analyzed by a sequential procedure. First, the fractional outflow curve C sucr (t) of the extracellular marker [U-14 C]sucrose was fitted by eq. 3, whereby f cath (s) accounts for the catheter and f B (s) includes the large vessel transit time,
and the transit time density (TTD) of the nonpermeating indicator is given by
with
Equation 5 is the Laplace transform of the inverse Gaussian density function with mean MTT i and relative dispersion. Equations 3 to 5 have been shown to adequately describe the TTD of vascular markers in the perfused rat liver (Weiss et al., 1997) .
Catheter transit time density was calculated by an independent experiment fitting eqs. 4 and 5 to the catheter system outflow profile. The four parameters describing f cath (s) were then fixed while fitting the liver outflow data.
The mean transit time of the extracellular reference, MTT B ϭ ͐ 0 ϱ tf B (t)dt, is given by
is the sum of the sinusoidal plasma space volume accessible to sucrose, and the Disse space, V B ϭ V Plasma ϩ V Disse . Q(1 Ϫ hematocrit) denotes the plasma flow rate. Sucrose does not distribute into erythrocytes; therefore this extracellular space value has to be corrected for hematocrit (Varin and Huet, 1985) . Second, using this information the outflow concentration data of the permeating drugs, C(t), were analyzed, i.e., the parameters MTT i, (i ϭ 1, 2), and p of the individual fits of [U-14 C]sucrose data were substituted as fixed parameters in f B (s) of the model (eq. 2):
and the parameters k in , k out , K v, K b , and k e were estimated. In this study, a uniform K v ϭ 0.25 was assumed in monensin treatment (the K v value was estimated from the volume ratios of the subcellular compartments to the remaining cytoplasmic fraction: 0.21 for mitochondria plus lysosomes and 0.79 for cytosol (Rhoades and Pflanzer, 1996) and used as a fixed parameter in data fitting to obtain k in , k e , k out , and K b. The parameters k in , k out , k e , and K b were then fixed to estimate K v for the data in the not monensin-treated groups.
The relative contribution of ion-trapping, intracellular binding and distribution of unbound drug for hepatic sequestration of the three model drugs is therefore given by
respectively. The cellular distribution volume of water was estimated by fitting the 3 H-water outflow data with eq. 7 using the density function for water f W (s) instead of f(s). The latter differ only with regard to the respective tissue retention time densities f y (s) assuming no cytoplasmic binding of water and k out,w ϭ k in,w v c,w where v c,w denotes the normalized cellular water volume eq. 1 for well mixed intracellular distribution reduces (Weiss et al., 2000) f y, w ͑s͒ ϭ k in, w /v c, w k in, w /v c, w ϩ s
and is substituted in eqs. 2 and 7. Nonparametric estimates of hepatic availability, mean transit time and normalized variance were determined from the outflow concentration versus time profiles for the reference from eqs. 10 to 13 using the trapezoidal method with exponential tail approximation.
AUC ϭ ͐ 0 ϱ C(t)dt is the area under the solute concentration versus time curve, Q is the perfusate flow rate, and D is the drug dose administered (expressed in molar equivalents). 
Statistical Analysis
All data are presented as mean Ϯ S.D. unless otherwise stated. Statistical analysis was performed using Tukey's post hoc or Student's t test where appropriate. A p Ͻ 0.05 was taken as significant.
Results
Figure 2 shows typical logarithms of measured and predicted (fitted data) time-outflow fraction profiles before and after monensin treatment for the three model cationic drugs antipyrine, atenolol, and propranolol. The peak outflow concentrations were in the order atenolol Ͻ antipyrine Ͻ propranolol and are inversely related to drug lipophilicity as defined by their individual log P app (atenolol 0.14, antipyrine 0.33, and propranolol 3.10). Monensin treatment did not affect the outflow concentration-time profile of antipyrine (with the lowest pK a and a low log P app ) but changed the outflow profiles of atenolol and propranolol (Fig. 2) . The effect of jpet.aspetjournals.org monensin on the outflow profile of propranolol is dramatic (Fig. 2) and in the presence of monensin the profile assumes a shape similar to antipyrine (Fig. 2) . The outflow profiles of antipyrine (as a positive control that does not show iontrapping) remained unchanged and were virtually superimposed before and after treatment (Fig. 2) . Table 1 shows the nonparametric moments parameters hepatic extraction, mean transit time, and normalized variance for the three model drugs. The mean transit time of propranolol showed treatment-induced significant differences (p Ͻ 0.01). No other differences for comparison of controls and monensin treatment groups were observed (p Ͼ 0.05; Table 1 ).
The model-derived kinetic parameters K v , K b , CL int , and PS for hepatic drug disposition of the three model drugs are summarized in Table 2 . The vesicular ion-trapping constant K v was significantly lower after monensin treatment for atenolol and propranolol (K v control/K v treatment: 30-and 35-fold, respectively; p Ͻ 0.001), but not for antipyrine. However, no changes induced by monensin treatment were observed for the intracellular binding constant, the intrinsic elimination clearance, or the permeability-surface area product values for the three model drugs (Table 2) .
A comparison of the predicted and observed model-derived ion-trapping parameter K v values are presented in Table 3 . The theoretical and observed values were in good agreement. Atenolol and propranolol both showed considerable ion-trapping (high K v values), whereas the corresponding value for antipyrine was relatively small (Table 3) .
The results of an in vitro binding, the calculated microsomal association constant and in vitro intrinsic elimination clearance for the three drugs in a microsomal protein preparation are shown in Table 4 . Monensin treatment had no effect on binding behavior or metabolic drug elimination. No differences before and after treatment were found to exist for the three model drugs (Table 4) . It is also apparent that the in vitro microsomal estimates of K b (Table 4) compare favorably with those obtained from modeling the perfused liver data ( Table 2 ). The microsomal CL int values obtained in vitro are also in general good agreement with the model-derived CL int values in the in situ isolated perfused liver study (Tables 2 and 4).
The relative contribution of ion-trapping, intracellular (microsomal and unspecific) binding, and the distribution of unbound drug to the hepatic retention of the three drugs are summarized in Fig. 3 . Ion-trapping is the most important determinant of hepatic drug retention for atenolol and the least important contributor for antipyrine, whereas ion-trapping and intracellular binding are equally important for hepatic drug retention for propranolol (Fig. 3) . The distribution of unbound drug is the least important determinant for propranolol and the most important for antipyrine (Fig. 3) .
Discussion
The study presented here was undertaken to define the relative importance of intracellular binding, vesicular (lysosomal and mitochondrial) drug sequestration, and distribution of unbound drug as determinants of hepatic solute retention and also to investigate the relative importance of pK a lipophilicity for this process. Monensin was used to determine the relative contribution of vesicular ion-trapping in the hepatic retention of three model cationic drugs: atenolol, antipyrine, and propranolol. In vitro microsomal studies produced independent estimates of microsomal binding and intrinsic clearance that showed that monensin treatment does not affect these parameters and therefore can be used to estimate the contribution of vesicular ion-trapping to hepatic drug retention. The difference in K b calculated from in vitro microsomal data (Table 4 ) and the model-derived values from the perfused liver (Table 2) suggests that microsomal binding accounts for most of hepatic binding, as has been previously suggested for the normal rat and human livers (McLure et al., 2000; Hung et al., 2002) . A comparison of CL int values obtained in the in vitro study (Table 4) and results from the in situ liver perfusion (Table 2) show the reliability and suitability of the model used in the study.
In this investigation, the intact, viable, perfused in situ rat liver was used to study sequestration of basic drugs in acidic organelles of the liver. By using monensin as an inhibitor of vesicular sequestration, the processes governing the pharmacokinetic events in the disposition of these basic drugs were quantified. This is, as far as we are aware, the first attempt to determine the differential contribution of ion-trapping, microsomal binding, and distribution of unbound solute to the hepatic retention of basic drugs with differing physicochemical properties in the isolated perfused rat liver.
Previous studies with ionophores have used cultured hepatocytes (Lake et al., 1987; Myers et al., 1995) or liver slices (Daniel et al., 1995; Daniel and Wojcikowski, 1999a) . Lake et al., (1987) used monensin to characterize the number of acidic compartments in intact hepatocytes (Lake et al., 1987; Myers et al., 1995) , and Myers et al. (Lake et al., 1987; Myers et al., 1995) applied flow cytometry to make dynamic measurements of the lysosomal pH in living hepatocytes. The studies of Daniel et al. (1995) have been focused on the contribution of two factors, nonspecific drug binding to membrane phospholipids and ion-trapping of cationic drugs in tissue slices (Daniel et al., 1995; Daniel and Wojcikowski, 1999a) and the contribution of lysosomal trapping to the total TABLE 1 Non-parametric moments for model cationic drugs (mean Ϯ S.D., n ϭ 6) There were significant differences between controls and treatment groups for the mean transit time of propranolol (** p Ͻ 0.01). No other differences for the non-parametric moment parameters were found between control and treatment groups (p Ͼ 0.05). tissue uptake of neuroleptics (Daniel et al., 1995; Daniel and Wojcikowski, 1999a) . The extent of uptake of drugs into tissue slices was found to be tissue-specific, and the contribution of the two uptake mechanisms to be strongly drugdependent (the contribution of ion-trapping to the total drug uptake of perazine in the liver was given as 40%). The model used in our investigation differs from previous studies in that a perfused liver, in which the vascular hepatic architecture remains intact and the liver is oxygenated by red blood cells, was used to ensure optimal hepatic vitality and drug extraction in the perfused organ in situ. In our present study, we characterized both hepatic extraction and retention, including the respective relative contribution of ion-trapping, and also those of microsomal protein binding (the major hepatic factor contributing to drug binding; Hung et al., 2002) and of unbound drug uptake into the liver. The results are of considerable clinical relevance, especially for drugs that show high first pass hepatic extraction and are targeted to the liver, such as the statins (Garcia et al., 2003) or cytostatic drugs.
Analysis of hepatic extraction, mean transit time, and normalized variance by moments showed that there were no differences in these parameters for the three drugs before and after monensin treatment (Table 1) with the exception of propranolol that showed a decrease in mean transit time from 119 to 79.5 s post-treatment. This change is also evident in Fig. 2 , where the change in outflow profile and especially the different tail sections of the curves are indicative of this change. Together with monensin not affecting in vitro microsomal binding and intrinsic clearance, it is evident that the major impact of monensin is on ion-trapping of basic drugs in hepatic acidic vesicles, as has been shown previously by histology (Lake et al., 1987) .
According to the hepatic transport model used in this work (Fig. 1) , hepatic extraction is affected by metabolism, permeability, and perfusate flow, whereas the mean transit time is defined not only by these parameters but also by ion-trapping (K v ) and microsomal binding (K b ). Confirmation of the relationships is provided by an independent assessment of the effects of monensin on hepatic extraction and mean transit time (Table 1) , relative to controls. Furthermore, the in vitro study suggests that the drug fraction unbound by microsomal protein (surrogate of K b ) remains unchanged by monensin treatment (Table 4) . Changes in mean transit time after monensin treatment are most evident for propranolol using a model-independent approach (Table 1 ). The change in K v (Table 2) is consistent with this change in mean transit time due to ion-trapping.
The comparison of kinetic parameters before and after monensin treatment showed no differences for intracellular binding, intrinsic elimination clearance, or permeability (Table 2). Differences between control and treatment groups were observed for the vesicular ion-trapping of atenolol and propranolol (with their relatively high pK a ) but not for antipyrine ( Table 2 ). The post-treatment ion-trapping was estimated from the volume ratios of the subcellular compartments to the remaining cytoplasmic fraction and fixed at 0.25. This calculated value is very close to the ion-trapping found for antipyrine in the control group. Because ion-trapping is defined by the relative permeation rates into and out of the acidic vesicles, it becomes obvious that this parameter is a potent marker of vesicular ion-trapping. 
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Ion-trapping may be estimated from considerations of the pHs and fractional volumes of the various cellular components, assuming that distribution is instantaneous and the resulting steady-state ratios are reflect in the observed ratios from dynamic (nonsteady-state) studies. When the unbound drug concentration is assumed to be identical in both the intracellular and perfusate compartments, the intracellular to perfusate concentration ratio for a drug with a given pK a is given by 1 ϩ 10 pKaϪpHi /1 ϩ 10 pKaϪpHp (Goldstein et al., 1974) , where pH i is the intracellular pH and pH p is the perfusate pH (Table 3) . A comparison of the predicted iontrapping and the experimental ratios obtained by data fitting showed good similarity (Table 3) . It is recognized that the predicted ion-trapping is only an approximation as a range of pHs have been reported for intracellular pH (7.19 -7.29 ) (Le Couteur et al., 1993; Burns et al., 1999; Pietri et al., 2001) , mitochondrial pH (6.7-7.0) (Soboll et al., 1980) , and lysosomal pH (4 -5) (MacIntyre and Cutler, 1988; Myers et al., 1995; Proost et al., 1997) as well as differing lysosomal fractional volumes (0.68 -1%) (Rhoades and Pflanzer, 1996) .
The relative contributions of ion-trapping, microsomal binding and distribution of unbound drug to the hepatic sequestration of the three model drugs is summarized in Fig.  3 . It is apparent that neither pK a nor lipophilicity is a sole determinant of drug distribution. Whereas the retention of the polar drug atenolol with its high pK a is mainly determined by ion-trapping, and intracellular binding and distribution of unbound drug contribute only in a minor way, the retention of the neutral drug antipyrine is mainly decided by the distribution of intracellular unbound drug. The combination of high lipophilicity and high pK a of propranolol results in intracellular binding and ion-trapping determining its retention in equal parts (Fig. 3) .
It has been suggested that lysosomes account for as much as 10% of the distribution of the basic drugs imipramine, biperiden, and chlorpromazine in the rat liver (Ishizaki et al., 1996) . This effect is likely to be reduced by the neutralization of the lysosomal and mitochondrial pH at the higher therapeutic plasma concentration of the drugs. Furthermore it has been shown that external propranolol concentrations of 10 Ϫ6 , 10 Ϫ5 , and 10 Ϫ4 M increased the intralysosomal pH in highly purified rat liver, from pH 5.5 to approximate pHs of 5.6, 5.75, and 6.1, respectively (Ishizaki et al., 2000) . Given that the uptake of imipramine into purified lysosomes shows a lack of dependence on either temperature or countertransport (Ishizaki et al., 2000) , it is probable that a passive ion-trapping mechanism is responsible for the uptake of cationic drugs into lysosomes. The effect of neutralization of pH on uptake into mitochondria is less marked because their pH is only an order of magnitude different to physiological pH, whereas the intralysosomal differs by several orders of magnitude. Ishizaki et al. (1996) also showed that weak bases suppressed uptake of bases into lysosomes more than into mitochondria.
Could abolishing of the ion-trapping effect be justified therapeutically? Monensin is routinely used in the cattle and a Vesicular to cytosolic concentration ratio ϭ (1 ϩ 10 pKa Ϫ pHv)/(1 ϩ 10 pKa Ϫ pHi) (Myers et al., 1995) , where pHi Ϸ 7.27 is the assumed cytosolic pH (Le Couteur et al., 1993) , pHv Ϸ 4.4 is the assumed lysosomal pH (Daniel et al., 2001 ) and pHv Ϸ 6.67 is the assumed mitochondrial pH in the fasted state (Pietri et al., 2001) .
b Given that of lysosomal and mitochondrial to the cytosolic fraction is 1 and 20% (Rhoades and Pflanzer, 1996) , the overall unbound drug vesicles/intracellular distribution ratio (v:i) for the three model drugs can be estimated from the individual organelle volume fraction and concentration ratio above using the equation:
c Data fitting results using the physiological two-phase organ pharmacokinetic model. at ASPET Journals on July 7, 2017 jpet.aspetjournals.org Downloaded from poultry industry as feed additive, and lysosomal inhibitors have already been proposed as possible potent antimalarial therapeutics (Gumila et al., 1997) and also been considered as anticancer drugs (Singh et al., 1999; Park et al., 2002) . However, monensin has been characterized by a narrow safety margin and may cause lethal toxicoses, especially when coadministered with other drugs (Nebbia et al., 1999) . Furthermore, accidental poisoning in animals (Nebbia et al., 1999) and an isolated case of lethal monensin ingestion in a human patient suggest that large doses of lysosomal inhibitors must be considered potentially dangerous for humans (Caldeira et al., 2001) . Nevertheless the possibility to use lysosomal inhibitors to manipulate hepatic (or pulmonary) drug extraction to achieve a higher systemic availability for drugs that show a pronounced first pass effect is of interest.
In conclusion, the relative contributions of ion-trapping, intracellular binding, and distribution of unbound drug of the basic drugs atenolol, antipyrine, and propranolol and the importance of pK a and lipophilicity for total hepatocellular retention were determined. Ion-trapping is the dominant determinant of intracellular distribution of a polar drug with high pK a and low lipophilicity (i.e., atenolol) but for a drug with a comparable high pK a and high lipophilicity (i.e., propranolol) intracellular binding and ion-trapping are equally important for hepatic drug retention. The intracellular distribution of a drug with low pK a and low lipophilicity (i.e., antipyrine) is characterized mainly by the distribution of intracellular unbound drug. The methodology used in this study may become a powerful and important tool in assessing and predicting differential intracellular drug distribution and retention pharmacokinetics.
